Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib (BOS) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥ 2 tyrosine kinase inhibitors (TKIs) Meeting Abstract
| Authors: | Hochhaus, A.; Boquimpani, C.; Rea, D.; Minami, Y.; Lomaia, E.; Voloshin, S.; Turkina, A. G.; Kim, D. W.; Apperley, J.; Cortes, J. E.; Abdo, A.; Fogliatto, L. M.; Kim, D. D. H.; le Coutre, P. D.; Saussele, S.; Annunziata, M.; Hughes, T. P.; Chaudhri, N. A.; Chee, L. C. Y.; Gutierrez, V. G.; Sasaki, K.; Aimone, P.; Allepuz, A.; Quenet, S.; Bedoucha, V.; Mauro, M. J. |
| Abstract Title: | Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib (BOS) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥ 2 tyrosine kinase inhibitors (TKIs) |
| Meeting Title: | 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-19 |
| Language: | English |
| ACCESSION: | WOS:000614257400005 |
| DOI: | 10.1182/blood-2020-143816 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA-4 -- Source: Wos |
